Davis Polk advised the initial purchasers on a Rule 144A offering by Jazz Investments I Limited, a wholly owned subsidiary of Jazz Pharmaceuticals plc, of $850 million aggregate principal amount of its 2.000% exchangeable senior notes due 2026.

Headquartered in Dublin, Ireland, Jazz Pharmaceuticals is global biopharmaceutical company dedicated to developing and commercializing life-changing medicines for people with serious diseases – often with limited or no options. Jazz Pharmaceuticals has a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. Jazz Pharmaceuticals’ focus is in neuroscience, including sleep medicine and movement disorders and in oncology, including hematologic and solid tumors.

The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Jonathan Bye and Paula Gergen. Partner Po Sit and associate Lex L. Varga provided tax advice. Counsel Bonnie Chen and associate Jennifer Leather provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post